Ganitumab

Source: Wikipedia, the free encyclopedia.
Ganitumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
TargetIGF-1R
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
KEGG
Chemical and physical data
FormulaC6472H10028N1728O2020S42
Molar mass145712.01 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Ganitumab is a human monoclonal antibody against type 1 insulin-like growth factor receptor (

IGF1R), designed for the treatment of cancers.[1][2]

Ganitumab was developed by Amgen. A phase III clinical trial (for metastatic pancreatic cancer) was abandoned in August 2012.[3][4]

References

  1. ^ "Statement On A Nonproprietary Name Adopted By The USAN Council: Ganitumab" (PDF). American MedicaAssociation.
  2. S2CID 7318164
    .
  3. ^ "Amgen Pulls Cancer Drug". 10 Aug 2012. Archived from the original on 2013-07-23.
  4. ^ "Amgen (AMGN) Terminates Ganitumab Pancreatic Cancer Trial". 8 Aug 2012. Archived from the original on 2012-08-10.
Retrieved from "https://en.wikipedia.org/w/index.php?title=Ganitumab&oldid=1155757244"